Study S000771

Efficacy and Safety of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: A Randomised, Double-blind, Placebo Controlled, Parallel Group, Multi-centre, 28-week Trial

ClinicalTrials.gov record

Registration

Registration: NCT04487743
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: QUADRUPLE
Status: UNKNOWN
Enrollment: 300
Start: 2020-05-09
Primary completion: 2022-06
Lead sponsor: Xiangya Hospital of Central South University
Conditions: Obesity
Interventions: DRUG:Liraglutide; DRUG:placebo
Results posted: FALSE
Secondary identifiers: OTHER_GRANT:HDSJ19LLLT

Registered primary outcomes

Mean Change From Baseline in Fasting Body Weight [Week 0, Week 28]
Percentage of Subjects Losing at Least 5% of Baseline Fasting Body Weight. [Week 28]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.